FDA okays four-strain flu shot.
The FDA approved Fluarix Quadrivalent vaccine for vaccination against seasonal influenza in people aged 3 years and older. Quadrivalent seasonal influenza vaccines contain two influenza A and two influenza B strains, instead of trivalent seasonal influenza vaccines' two A strains and one B strain.
The newly approved quadrivalent vaccine contains two strains of type A influenza (A/H1N1 and A/H3N2) and two type B strains, a Yamagata lineage strain and a Victoria lineage strain.
This is second quadrivalent influenza vaccine to be approved by the agency. In February, the FDA approved a quadrivalent version of the FluMist influenza vaccine, the intranasal influenza vaccine manufactured by MedImmune, in people aged 2-49 years.
The Fluarix Quadrivalent vaccine will be available in time for the 20132014 influenza season, manufacturer GlaxoSmithKline said in a statement. GSK also plans to fulfill orders for the trivalent version of Fluarix, because health care providers typically order influenza vaccine about a year before the next influenza season.
The Fluarix Quadrivalent vaccine has not been approved in any country other than the United States, according to GSK.
|Printer friendly Cite/link Email Feedback|
|Publication:||Internal Medicine News|
|Date:||Jan 1, 2013|
|Previous Article:||Flu activity gets early jump, continues to rise.|
|Next Article:||APA approves final DSM-5 criteria.|